Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review

Frank Cobelens1,2*, Sanne van Kampen2,3, Eleanor Ochodo2,4, Rifat Atun5, Christian Lienhardt6¤

1 Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands, 2 Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands, 3 KNCV Tuberculosis Foundation, The Hague, The Netherlands, 4 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands, 5 Imperial College London, London, United Kingdom, 6 Stop TB Partnership, World Health Organization (WHO), Geneva, Switzerland

Abstract

Background: Several interventions for tuberculosis (TB) control have been recommended by the World Health Organization (WHO) over the past decade. These include isoniazid preventive therapy (IPT) for HIV-infected individuals and household contacts of infectious TB patients, diagnostic algorithms for rule-in or rule-out of smear-negative pulmonary TB, and programmatic treatment for multidrug-resistant TB. There is no systematically collected data on the type of evidence that is publicly available to guide the scale-up of these interventions in low- and middle-income countries. We investigated the availability of published evidence on their effectiveness, delivery, and cost-effectiveness that policy makers need for scaling-up these interventions at country level.

Methods and Findings: PubMed, Web of Science, EMBASE, and several regional databases were searched for studies published from 1 January 1990 through 31 March 2012 that assessed health outcomes, delivery aspects, or cost-effectiveness for any of these interventions in low- or middle-income countries. Selected studies were evaluated for their objective(s), design, geographical and institutional setting, and generalizability. Studies reporting health outcomes were categorized as primarily addressing efficacy or effectiveness of the intervention. These criteria were used to draw landscapes of published research. We identified 59 studies on IPT in HIV infection, 14 on IPT in household contacts, 44 on rule-in diagnosis, 19 on rule-out diagnosis, and 72 on second-line treatment. Comparative effectiveness studies were relatively few (n = 9) and limited to South America and sub-Saharan Africa for IPT in HIV-infection, absent for IPT in household contacts, and rare for second-line treatment (n = 3). Evaluations of diagnostic and screening algorithms were more frequent (n = 19) but geographically clustered and mainly of non-comparative design. Fifty-four studies evaluated ways of delivering these interventions, and nine addressed their cost-effectiveness.

Conclusions: There are substantial gaps in published evidence for scale-up for five WHO-recommended TB interventions settings at country level, which for many countries possibly precludes program-wide implementation of these interventions. There is a strong need for rigorous operational research studies to be carried out in programmatic settings to inform on best use of existing and new interventions in TB control.

Please see later in the article for the Editors’ Summary.

References

Citation: Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C (2012) Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review. PLoS Med 9(12): e1001358. doi:10.1371/journal.pmed.1001358

Academic Editor: Carlton Evans, Universidad Peruana Cayetano Heredia, Peru

Received April 23, 2011; Accepted November 8, 2012; Published December 18, 2012

Copyright: © 2012 Cobelens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The Stop TB Partnership and the Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM) were involved in the study design and the preparation of the manuscript as this study was commissioned within a larger frame project aiming at identifying priorities for operational research in tuberculosis, with the view to assist countries in preparing and conducting operational research to improve tuberculosis control. Results of the study were presented and discussed in a workshop laying the ground for a manual on TB operational research. The Stop TB Partnership and GFATM had no influence on the analysis, data interpretation and results, or in the decision to submit the (revised) manuscript for publication.

Competing Interests: The authors have declared that no competing interests exist.

Abbreviations: IPT, isoniazid preventive therapy; TB, tuberculosis; WHO, World Health Organization.

* E-mail: f.cobelens@aighd.org

¤ Current address: StopTB Department, WHO, Geneva, Switzerland
Introduction

Despite a widely adopted global strategy to control the disease, tuberculosis (TB) remains a major health problem, particularly in resource-poor countries [1]. New interventions are needed to improve diagnosis, treatment, and prevention of infection and disease, such as new technologies (e.g., diagnostic) or products (e.g., drugs, vaccines), but also novel use of existing technologies and products (e.g., alternative diagnostic algorithms, novel ways of improving treatment adherence) [2,3]. Policy makers need to consider how these interventions can be adopted by TB control programs and implemented at a program-wide scale. This evaluation involves policy choices at several levels—global, national, and local—that need to be informed by evidence that has been collected and interpreted in a systematic and reproducible way [4], especially evidence on intervention effectiveness. While clinical trials (e.g., of new drugs) or laboratory-based comparisons against gold-standard methods (e.g., of new diagnostics) lay the basis for such evidence by establishing the efficacy under optimally controlled conditions, the effectiveness of an intervention quantifies effects in real-life health care settings [5], as measured by outcomes that are relevant to TB control (e.g., the number of patients cured, or the number of TB cases prevented) as well as outcomes that are relevant to patients (e.g., earlier diagnosis and cure, improved access to care) [4,6]. In addition, policy makers need to understand how an efficacious intervention can best be delivered in various contexts, in particular the conditions and requirements that determine implementation success or failure. Such conditions may include, for example, methods for optimizing treatment adherence, or for ensuring access to diagnostic procedures [7–9]. Finally, policy makers in resource-constrained settings need to know whether an intervention is the most cost-effective way of improving TB control compared to alternative interventions [10]. Collectively, these three types of information can provide the “evidence for scale-up,” addressing whether and how a new intervention will improve TB control in a cost-effective way at program-wide scale.

Over the past decade, several new interventions in TB control have been developed and recommended in World Health Organization (WHO) guidelines [11]. While recommendations for new interventions are usually based on evidence for efficacy arising from controlled studies, little is known about their effectiveness, the requirements for optimum delivery, and their cost-effectiveness when implemented in various epidemiological and resource conditions. This limited evidence, along with other factors, might have hindered wide-scale use of potentially effective interventions [12]. There are currently no systematically collected data on the availability of evidence for scale-up of newly recommended interventions for TB control. Therefore, we conducted a systematic review of published study reports of five related interventions that have been recommended by the WHO over the past decade, and for which evidence guiding scale-up would be needed. The five interventions were selected as representing direct actions to be carried out at the country level to improve TB control with regard to prevention, diagnosis, and treatment and covering a large spectrum of situations. This made it possible to assess what research had been done to guide implementation under a variety of epidemiological conditions (e.g., high or low HIV incidence, high or low burden of TB drug resistance).

These interventions are: (i) isoniazid preventive therapy (IPT) for preventing TB disease among HIV-infected individuals; (ii) IPT for preventing TB disease among household contacts of infectious TB patients; (iii) clinical algorithms for diagnosing smear-negative TB disease in patients seeking care (“rule-in algorithms”); (iv) screening algorithms for excluding TB disease in HIV-infected individuals eligible for preventive therapy (“rule-out algorithms”); and (v) programmatic provision of second-line treatment for multidrug-resistant TB. All were recommended over the past decade [13-17]; several have been updated since. For each of these interventions, we appraised published studies critically with respect to their objectives, the designs used (how were these questions addressed?), the settings in which they were performed, and their generalizability, giving particular attention to the extent to which the study findings reflected the conditions of, and the patient populations covered by, routine TB services.

Methods

For each of the five interventions we searched the MEDLINE, EMBASE, Web of Science, and several regional databases (Index Medicus for the Eastern Mediterranean Region, SaudMed, INMDMED, HERDIN, Thai Index Medicus, LILACS, African Index Medicus, Koerreamed Medicus, Aidsthaidata) for research papers published between 1 January 1990 and 31 March 2012 following a predefined protocol (Texts S1 and S2). All databases searched are available online; we only used databases from researchers that had been peer reviewed and published, and we only included published studies. To maximize the number of publications evaluating effectiveness, delivery, and cost-effectiveness of these interventions, we initially included all publications identified by key word searches (Text S3). For each intervention, two reviewers (EO and FC) independently selected publications from this list on the basis of titles and abstracts, applying preset criteria (Box 1). Additional manual search of the reference lists of reviews was performed; publications thus identified were checked with the initial selections and added if lacking. Since the International Journal of Tuberculosis and Lung Disease has published extensively on the subject of interest, we performed an additional manual search of this journal on a randomly selected 10% of its issues to check if the database search included all relevant titles; we found no publications that were not identified in our initial searches. Only papers written in English, French, Spanish, Portuguese, or German were included.

Data from all selected papers were entered into a MS Excel database (Microsoft Corp), including study objectives, design, settings, and results. Two reviewers (SvK and FC) independently appraised each included publication; disagreement was solved by consensus (FC). In addition to the key evaluation criteria (objective(s), design, setting, generalizability), for studies that reported health outcomes we appraised the extent to which they addressed effectiveness rather than efficacy (Box 2). Our review did not aim to summarize the results of the studies, and by its nature included studies of highly varying designs and methodologies. Therefore we did not perform any quality assessments.

Finally, we evaluated the distribution of the studies according to their geographical location in four global regions (Central/South America, sub-Saharan Africa, Middle East and South Asia, and East and Southeast Asia), their type (effectiveness, cost-effectiveness and delivery studies), their design (comparative or non-comparative), and the setting in which they were conducted (routine/programmatic, research, or mixed routine-research). This assessment allowed us to assess the general landscape of interventions arising from these data, thereafter referred to as “the research landscape.” Because of the high MDR-TB prevalence and specific organization of the TB control system,
Results

for second-line treatment we added the former Soviet Union as a separate region.

The funders of this study (the Stop TB Partnership and Global Fund to Fight AIDS, Tuberculosis and Malaria) were involved in study design and preparation of the manuscript but did not influence the data collection, analysis, or decision to publish.

4. Screening algorithms for excluding smear-negative TB:

- use in immunocompromised individuals other than HIV-infected
- clinical studies limited to specific diagnostic tools (e.g., bronchoscopy, PCR) and not addressing combinations of tools (i.e., diagnostic algorithms)
- proof-of-principle studies of diagnostic methods
- studies reporting the sensitivity of diagnostic tools only
- studies only assessing predictors of smear-negative TB
- (i.e., not evaluating or developing a clinical algorithm)

5. Second-line treatment of MDR-TB:

- pharmacological studies
- studies specifically aimed at assessing effects of drug resistance on treatment outcomes
- studies on resistance prevalence and patterns; studies on diagnosis of drug-resistant TB
- genetic studies
- retrospective case series reporting outcome data on fewer than 50 patients
- studies on surgical interventions only describing the patients who had surgery (studies that describe a cohort of MDR patients of whom a portion had surgery were included)

Isoniazid Preventive Therapy

Of 4,418 titles and abstracts screened we included 73 studies in the analysis (Figure 1), of which two were identified from regional databases only. Fifty-seven studies addressed IPT in HIV-infected individuals, 14 addressed IPT in household contacts (13 in children, one in all age groups), and two addressed IPT in miners in South Africa. Since HIV prevalence in these study populations was high we included the latter study in the HIV category, bringing the total number of HIV studies to 59. Thirty-six of the 73 studies followed a comparative research design (45.2%), including 19 individually randomized trials (all among HIV-infected individuals). Although two studies included data from group-randomized trials [18,19], none reported analyses of trial outcomes. Twenty-three prospective and ten retrospective cohort studies used a non-comparative design. Sixty-four of the 73 single-country studies (90.1%) were conducted in countries with HIV prevalence among TB patients of ≥5%. The majority of these studies were undertaken in sub-Saharan Africa (45; 61.6%) and the Americas (14; 19.2%) (Figures 2 and 3). Two-thirds of all studies (50, 68.5%) were conducted in just five countries, namely South Africa (22), Uganda (9), Brazil (8), Thailand (6), and Haiti (5), and the majority by the same research groups. Twenty-two (30.1%) studies were in research settings, and 39 (53.4%) in routine settings.

We categorized the results of 35 studies (47.9%) as generalizable irrespective of setting, 25 (34.2%) as generalizable to similar epidemiological and health care settings, and four as not generalizable beyond local or national setting.

There was a sharp increase in numbers of studies from 2006 onwards, when 46 of the 73 studies (63.0%) were published.

Box 1. Selection Criteria for Papers

Inclusion criteria

- full-text papers reporting on human studies performed in low- or middle-income countries
- abstract in English; publication written in English, French, Spanish, German, or Portuguese
- publications that did not address the selected interventions and/or evaluations of these interventions
- mathematical or decision modeling studies not directly based on observations on the intervention concerned (hypothetical cohort models)
- costing studies without an effectiveness component
- reviews

General exclusion criteria

- case reports
- pharmacological studies
- retrospective case series reporting outcome data on fewer than 50 patients
- studies only assessing predictors of smear-negative TB
- (i.e., not evaluating or developing a clinical algorithm)

Intervention-specific exclusion criteria

1. IPT among HIV-infected individuals:

- use in immunocompromised individuals other than HIV-infected, including silicosis in low HIV prevalence populations

2. IPT among household contacts:

- use in immunocompromised individuals other than HIV-infected

3. Clinical algorithms for diagnosing smear-negative TB:

- use in immunocompromised individuals other than HIV-infected
- studies only assessing predictors of smear-negative TB
- (i.e., not evaluating or developing a clinical algorithm)
null
1. Titles & abstracts screened from PUBMED, WOS & EMBASE:
   a) IPT: n=2512
   b) Clinical algorithms: n=2191
   c) Second-line treatment: n=2234
2. Titles & abstracts screened from regional databases*:
   a) IPT: n=1906
   b) Clinical algorithms: n=1243
   c) Second-line treatment: n=1403
3. Number of records identified from other sources: n=4

Number of irrelevant titles & abstracts:
   a) IPT: n=4106
   b) Clinical algorithms: n=3275
   c) Second-line treatment: n=3716

Number of duplicates excluded:
   a) IPT: n=67
   b) Clinical algorithms: n=36
   c) Second-line treatment: n=14

Number of full texts assessed for eligibility:
   a) IPT: n=108
   b) Clinical algorithms: n=87
   c) Second-line treatment: n=93

Number of full texts excluded:
   a) IPT: n=33 for done outside target countries or populations (4); not reporting evaluation data (12); cost-effectiveness using effectiveness parameters derived from the literature (7); not addressing preventive therapy (5); only reporting test accuracy data on an assay for measuring isoniazid drug levels (1); only addressing methodology (2); full text language (2).
   b) Clinical algorithms: n=24 for not reporting evaluation data (11); only evaluating single test (6); not addressing smear-negative TB (7).
   c) Second-line treatment: n=20 for not addressing second-line treatment (7), not reporting evaluation data (6); retrospective case series of <50 patients (5); only reporting costs without effectiveness data (2).

Number of full texts not obtained:
   a) IPT: n=2
   b) Clinical algorithms: n=0
   c) Second-line treatment: n=1

Figure 1. Flow chart for selection of articles for isoniazid preventive therapy (a), clinical algorithms for diagnosis/screening of smear-negative pulmonary TB (b), and second-line TB treatment (c).
doi:10.1371/journal.pmed.1001358.g001
| Appraisal | HIV Infection, n = 59 | Household Contacts, n = 14 | Total, n = 73 |
|-----------|-----------------------|-----------------------------|--------------|
|           | Major Category | Minor Category | Major Category | Minor Category | Major Category | Minor Category |
| **Year of publication** | | | | | | |
| 1990–1995 | 2 | 0 | 2 | | | |
| 1996–2000 | 11 | 1 | 12 | | | |
| 2001–2005 | 11 | 2 | 13 | | | |
| 2006–2012 | 35 | 11 | 46 | | | |
| **Objective** | | | | | | |
| Effects on health outcomes | | | | | | |
| Evaluation of IPT for preventing TB or progression to AIDS | 44 | 3 | 47 | | | |
| Comparing IPT versus no IPT only | 11 | 0 | 11 | | | |
| Comparing various regimens and dosing schedules | 9 | 0 | 9 | | | |
| Comparing various durations | 2 | 0 | 2 | | | |
| Comparing various patient groups | 1 | 0 | 1 | | | |
| Comparing IPT versus HAART with or without IPT | 4 | 0 | 4 | | | |
| No comparison | 6 | 3 | 9 | | | |
| Frequency of and risk factors for adverse effects | 31 | 3 | 34 | | | |
| Drug resistance among TB cases during or after IPT | 6 | 0 | 6 | | | |
| Delivery | 35 | 13 | 48 | | | |
| Evaluation of IPT completion/adherence rate | | | | | | |
| Comparing different regimens | 2 | 1 | 3 | | | |
| Comparing interventions for enhancing completion and/or adherence | 1 | 0 | 1 | | | |
| Frequency of and risk factors for non-completion or non-adherence | 28 | 6 | 34 | | | |
| Comparison of various IPT enrolment methods | 1 | 1 | 2 | | | |
| Barriers to implementation | 1 | 0 | 1 | | | |
| Assessment of practices | 2 | 5 | 7 | | | |
| Cost-effectiveness | 4 | 0 | 4 | | | |
| **Study design** | | | | | | |
| Comparative studies | 31 | 2 | 33 | | | |
| Individually randomized trials | 19 | 0 | 19 | | | |
| Group-randomized trials | 0 | 0 | 0 | | | |
| Non-randomized cohort comparisons | 10 | 1 | 11 | | | |
| Before-after comparisons | 1 | 0 | 1 | | | |
| Other | 1 | 1 | 2 | | | |
| Non-comparative studies | 28 | 12 | 40 | | | |
| Prospective cohort studies | 19 | 4 | 23 | | | |
| Retrospective cohort studies | 5 | 5 | 10 | | | |
| Cross-sectional clinical studies | 2 | 1 | 3 | | | |
| Surveys | 2 | 2 | 4 | | | |
| **Setting** | | | | | | |
| Estimated TB incidence per 100,000 population (2005) | 57* | 14 | 71* | | | |
| <50 | 2 | 1 | 3 | | | |
| 50–99 | 5 | 2 | 7 | | | |
| 100–299 | 7 | 3 | 10 | | | |
| ≥300 | 43 | 8 | 51 | | | |
| Estimated HIV prevalence among TB patients (2005) | 57* | 14 | 71* | | | |
| <5% | 3 | 4 | 7 | | | |
| ≥5% | 54 | 10 | 64 | | | |
evaluated predefined algorithms, eight were published in 2010 or 2011.

The landscape for rule-in diagnosis (Figure 4) shows that while effectiveness studies of diagnostic algorithms or combined diagnostics done in the relevant study population, i.e., individuals suspected to have TB, have been published from sub-Saharan Africa (n = 15), very few have come from other geographical regions. Only four of such effectiveness studies had a comparative design. There have been few studies on delivery aspects or cost-effectiveness, and again, there are very limited data from the Middle East/South Asian region.

Programmatic Provision of Second-Line Treatment for Multidrug-Resistant Tuberculosis

Of 3,637 titles and abstracts screened, we included 72 articles in the analysis (Figure 1), of which three were identified from regional databases only. The large majority (59, 81.9%) were non-comparative retrospective or prospective cohort studies that evaluated outcomes for individualized (i.e., guided by the individual drug resistance pattern) or standardized (i.e., guided by resistance patterns in the population) treatment (Table 3).

These articles included 11 studies that addressed XDR-TB, either uniquely or in combination with non-XDR MDR-TB, and nine that were done in a patient population with an HIV infection prevalence of ≥5%. Only one cohort study compared different second-line drug regimens for treatment outcomes using a non-randomized, group-wise before–after design [29]. Another cohort study compared outcomes for centralized versus decentralized treatment [30]. Two articles reported different analyses on the same patient cohort [31,32].

Fourteen studies (19.4%) addressed delivery issues, including five that assessed the effects of specific interventions for improving treatment adherence in a comparative design: two randomized-controlled trials comparing the effects of clinical pharmacist-directed patient education [33] and of telephone-assisted support [34]; a before–after comparison of decentralized patient management [35]; another before–after comparison of community- versus hospital-based treatment [36]; and a semi-quantitative case study of psychosocial support groups [37].

All of these studies also assessed predictors of successful or poor treatment outcomes, and two included cost-effectiveness analyses in programmatic settings. Eight of the cohort studies of treatment outcomes and nine additional studies specifically assessed frequency of and risk factors for adverse effects. One cohort study also reported on amplification of drug resistance and M. tuberculosis re-infection during treatment [38].

Of the 62 selected studies of second-line treatment that evaluated the associated health outcomes, almost all (58, 93.5%) were categorized as assessing effectiveness rather than efficacy.
Thirty-nine studies (54.2%) were from just five countries: Peru (11), South Africa (nine), South Korea (eight), India (six), and Latvia (five). This set of studies reflected to a large extent the research groups involved: 27 of these studies involved three research groups. Twenty-one (29.2%) studies were done in pilot projects of the “DOTS-Plus” approach to second-line treatment, and 48 (66.7%) in routine settings, including specialized clinics for 27 studies and programmatic settings for 21.

We categorized 53 studies (73.6%) as generalizable irrespective of setting. These were mainly cohort studies of treatment outcomes that were primarily determined by drug resistance pattern and drug regimen, except four that had highly setting-specific elements with regard to treatment completion (e.g., involving prison populations). All remaining studies were categorized as generalizable to similar epidemiological and health care settings.

All included studies were published after 1995; about three-quarters (53, 73.6%) were published from 2006 onwards. Of the 35 effectiveness studies done in programmatic or pilot settings, 13 were published since 2010.

The landscape arising from these data (Figure 6) shows that while non-comparative effectiveness studies (case series) in programmatic or pilot settings have been published from all regions of the world, studies comparing various interventions for their effectiveness outside research settings have been rare (n = 3). Studies on care delivery aspects are infrequent and those published are mainly from Peru. Studies specifically assessing cost-effectiveness are rare.

Discussion

Our systematic review demonstrates the paucity of published evidence for scale-up of five selected interventions for TB control in real-life conditions in various epidemiological and health care settings. In addition, the few published studies had limitations with regard to their design, their geographical distribution, and the settings in which they were conducted: studies aimed at assessing effectiveness rather than efficacy mainly had non-comparative designs, were geographically clustered (primarily in sub-Saharan Africa), and were often not done in sites or patient populations that reflect the routine health care settings in which the interventions need to be applied. Of the 208 reviewed studies for all five interventions combined, only about one-fourth (54 studies) evaluated ways of delivering these interventions in routine health care settings, and only nine assessed their cost-effectiveness, showing the limited evidence accrued for guiding their programmatic scale-up.

While these shortcomings are specific to each of these five interventions, there are a number of shared features. True real-life studies of effectiveness in programmatic settings are rare. While several studies assessed the efficacy of IPT under optimal conditions (such as in research settings) or in selected groups of patients, very few studies evaluated the effectiveness of IPT under routine conditions. Likewise, although in recent years a number of studies evaluating clinical algorithms for rule-in diagnosis of smear-negative TB or for rule-out of TB among HIV-infected individuals in programmatic settings have been published, the geographical distribution of these studies is patchy. For example, South Asia is consistently underrepresented.

In addition, very few studies have evaluated methods to optimize the delivery of the intervention. For example, while observational cohort studies of delivery of second-line treatment...
have been important to show its feasibility in resource-poor settings and identify best practices of treatment adherence, there are few published direct comparisons of such practices, and very few have used a comparative design.

Another common feature is the paucity of published economic evaluations of the recommended interventions according to our selection criteria (nine published cost-effectiveness analyses only, including none on IPT for contacts and only one on rule-out algorithms). This is not to say that no other cost-effectiveness analyses have been published. We found seven additional papers on cost-effectiveness modelling (all on IPT in HIV-infected individuals), but these studies modelled hypothetical cohorts that were not or only partially based on effectiveness and costing data as observed within single studies. Since these models tend to reflect ideal rather than real-life conditions, we considered these less relevant for decisions about scale-up at the country level.

Finally, and most importantly, relatively few studies had appropriate methods to evaluate interventions or the models to deliver these interventions. While a number of study designs can be used to demonstrate effectiveness of interventions, experimental or quasi-experimental methods with a comparative element are generally considered to provide the strongest evidence, particularly when the intervention is compared to existing practice. Since health interventions are often applied at the group level (e.g., entire clinics), such comparative studies preferably have randomized group-wise allocation [39]. This study design, also known as group- or cluster-randomized trial, has various extensions that allow study of intervention effects during implementation (e.g., the stepped wedge design) [40–42]. Although we became aware of two group-randomized comparative studies on IPT in HIV infection that are underway in Brazil and South Africa, respectively [18,19], we found no reports of group-randomized trials for any of the five interventions over the last decade. Increasingly used in other disease areas [43], this study design has found little application in TB. We believe this is a missed opportunity as the standardized diagnosis, treatment, and recording of the classical DOTS programs are particularly well suited for such studies, e.g., by randomizing diagnostic and treatment centres to one or the other intervention model [7,44]. In addition, when applied across programs, such standardization allows multi-country studies of similar approaches in different settings—such as the multi-site study on provision of second-line treatment by Nathanson et al. [45,46].

It should be noted, however, that (quasi-)experimental designs have potential drawbacks with regard to the representativeness of the study results for routine health care setting, as the research investment required tends to alter health care practice. Such interference may nonetheless be limited by issues such as basing data collection to a large extent on routine recording and reporting, and not collecting any clinical material beyond the intervention under study, which may also obviate the need for individual informed consent.

We found only a small number of studies that addressed delivery issues such as adherence to treatment or improved operations of existing diagnostics. This may be because these studies are conducted and reported locally, but not published in the peer-reviewed journals covered by our search, and because of publication bias leading to preferential publication of studies reporting successful outcomes [47].

Our review has a number of strengths. It assessed several TB control interventions in a single framework, allowing us to separate the characteristics that are common in the search for evidence for scale-up from those that are specific for each intervention. The framework that we applied categorizes studies according to a set of verifiable evaluation criteria, and even though the appraisal of study setting and generalizability of the study results had subjective elements, we defined these in a way that allows reproducibility for similar exercises on different interventions or diseases.
Table 2. Results for studies on clinical algorithms for diagnosis of smear-negative TB in patients presenting with symptoms (“rule-in”) and for screening of HIV-infected individuals (“rule-out”).

| Appraisal                | Rule in, \(n=44\) | Rule out, \(n=19\) | Total, \(n=63\) |
|--------------------------|---------------------|---------------------|-----------------|
|                          | Major Category      | Minor Category      | Major Category  | Minor Category |
| Year of publication      |                     |                     |                 |
| 1990–1995                | 2                   | 0                   | 2               |
| 1996–2000                | 7                   | 0                   | 7               |
| 2001–2005                | 12                  | 3                   | 15              |
| 2006–2012                | 23                  | 16                  | 39              |
| Objective                |                     |                     |                 |
| Effects on health outcomes| 34                  | 19                  | 53              |
| Evaluation of predefined algorithms | 15\(^a\) | 4       | 19              |
| Evaluation of diagnostic procedures |                     |                     |                 |
| With developing one or more algorithms | 8   | 12     | 20              |
| Without developing one or more algorithms | 3   | 2      | 5               |
| Evaluation of diagnostic procedures added to clinical algorithms\(^b\) | 8   | 1      | 9               |
| Delivery                 |                     |                     |                 |
| Improvement of sputum collection | 10  | 0      | 10              |
| Improvement of smear examination | 6   | 0      | 6               |
| Assessment of practices | 2       | 0      | 2               |
| Cost-effectiveness       | 2\(^c\)             | 1\(^c\)             | 3\(^c\)         |
| Study design             |                     |                     |                 |
| Comparisons of algorithms| 4                   | 0                   | 4               |
| Non-comparative studies  | 40                  | 19                  | 59              |
| Prospective cohort studies| 19               | 9                   | 28              |
| Retrospective cohort studies| 3               | 1                   | 4               |
| Cross-sectional studies  | 17                  | 9                   | 26              |
| Surveys                  | 1                   | 0                   | 1               |
| Study population         | 44                  | 19                  | 63              |
| All TB suspects          | 14                  | 6                   | 20              |
| All smear-negative TB suspects | 20         | 3                   | 23              |
| Smear-negative TB patients| 8                 | 0                   | 8               |
| All HIV+ patients        | 0                   | 4                   | 4               |
| All patients eligible for IPT cf. programmatic criteria | 0   | 3      | 3               |
| Patients notified with pneumonia (surveillance) | 1   | 0      | 1               |
| Patients notified with TB (surveillance) | 1   | 0      | 1               |
| Community-based survey   | 0                   | 2                   | 2               |
| Prison survey            | 0                   | 1                   | 1               |
| Setting                  |                     |                     |                 |
| Estimated TB incidence per 100,000 population (2005) | 44   | 18\(^d\) | 62\(^d\) |
| <50                      | 0                   | 0                   | 0               |
| 50–99                    | 6                   | 1                   | 7               |
| 100–299                  | 12                  | 3                   | 15              |
| 300+                     | 26                  | 14                  | 40              |
| Estimated HIV prevalence among TB patients (2005) | 44   | 17\(^e\) | 61\(^e\) |
| <5%                      | 12                  | 1                   | 13              |
| 5% or more               | 32                  | 16                  | 48              |
| Study location           | 44                  | 19                  | 63              |
| Research setting         | 2                   | 0                   | 2               |
| Mixed research – routine setting | 10  | 3      | 13              |
Our approach also has a number of limitations, in addition to those already mentioned. The interventions we selected do not cover all programmatic interventions in TB. However, the interventions we selected have all been recommended by the WHO and received attention as being poorly implemented, [48–51] despite being evidence-based with data showing that, under controlled circumstances, they improve prevention, diagnosis, or treatment of TB. In addition, our review only covered the period from 1990 to early 2012, and we may have missed studies published earlier. This time range could explain the small number of studies identified on IPT for household contacts, as this intervention was already recommended by WHO before 1990, based on randomized controlled trials of 12 or more months of isoniazid treatment among household contacts of infectious TB patients conducted in the 1960s in the USA, Puerto Rico, Mexico, Kenya, and The Philippines [52–55], as well as a community study in Alaska [56]. However, this timeframe was before WHO’s DOTS Strategy was launched mid-1990s [57], and most studies on effectiveness, delivery or cost-effectiveness of chemoprophylaxis of household contacts in DOTS-style TB control programs should have been published after that. The other interventions were recommended within the last decade, and impact studies are likely to have been done and published in the study period. Moreover, we found, for all interventions combined, only four studies published in the period 1990–1995, making it unlikely that our restriction of the review period caused us to miss studies that would have altered our conclusions.

Finally, although our search in addition to three global databases covered the most important literature databases for India, Africa, South- and Central America, the Arab subcontinent, the Philippines, Thailand, and South Korea, we did not search for publications in major languages such as Chinese, Arab, and Russian. However, among the over 4,000 titles we screened in regional databases, we found only five publications that had not yet been identified from the global databases, indicating that a more extensive search is unlikely to yield many more relevant publications and fundamentally different conclusions.

A detailed operational research agenda to address the implementation of WHO policies for TB control at country level was recently issued [58,59]. This review shows a number of gaps in the realization of this agenda. More studies are needed to show the effectiveness of IPT, including its effect on development of drug resistance, in HIV-infected persons as a programmatic intervention in countries representing a broad range of epidemiological and health system settings, notably in Asia. More studies are needed on IPT of household members outside of the context of HIV infection, and should include evaluation of cost-effectiveness. In addition, studies should assess approaches that enhance access to and adherence with each intervention as important delivery aspects. For clinical diagnosis of smear-negative TB, there is a need for studies that evaluate and compare effectiveness, delivery, and cost-effectiveness of rule-in and rule-out algorithms, especially outside sub-Saharan Africa. Furthermore, for provision of second-line treatment, different delivery models aimed at enhancing treatment adherence and management of adverse effects need to be evaluated in varied settings and compared for programme scalability.

This review showed the paucity of published data on the effectiveness, delivery, and cost-effectiveness of a selected number of new interventions in TB control in contexts where they need to be implemented. This lack of “evidence for scale-up” may be an important cause of the shortfall in implementation of these interventions in many countries. The recent diagnostic break-
Effectiveness studies, algorithm relate to studies designed to evaluate predefined clinical algorithms, and effectiveness studies, diagnostics to studies designed to evaluate combined diagnostic methods, both for diagnosing smear-negative TB among TB suspects done in routine or mixed routine-research settings. Delivery relates to studies designed to address diagnostic practices and improvement of smear examination or sputum collection to improve diagnosis of smear-negative TB. One study evaluated both combined diagnostic methods and a predefined clinical algorithm. Two cost-effectiveness studies were also included as evaluations of combined diagnostic methods.

doi:10.1371/journal.pmed.1001358.g004

Figure 4. Distribution of published studies on clinical algorithms for diagnosing smear-negative TB in patients presenting with symptoms (“rule-in”), by geography, objective, and study setting.

Effectiveness studies, algorithm related to studies designed to evaluate predefined clinical algorithms, and effectiveness studies, diagnostics to studies designed to evaluate combined diagnostic methods, both for excluding TB among HIV-infected individuals and done in routine or mixed routine-research settings. One cost-effectiveness study was also included as evaluation of combined diagnostic methods.

doi:10.1371/journal.pmed.1001358.g005

Figure 5. Distribution of published studies on clinical algorithms for screening for smear-negative TB in HIV-infected individuals (“rule-out”), by geography, objective, and study setting.
### Table 3. Results for studies on provision of second-line treatment for multidrug-resistant TB.

| Appraisal                          | Total, \( n = 72 \) |
|------------------------------------|---------------------|
|                                    | Major Category      | Minor Category |
| **Year of publication**            |                     |
| 1990–1995                          | 0                   |
| 1996–2000                          | 4                   |
| 2001–2005                          | 15                  |
| 2006–2011                          | 53                  |
| **Objective**                      |                     |
| Effects on health outcomes         |                     |
| Evaluation of treatment outcomes   | 59                  |
| of second-line treatment           |                     |
| Individualized regimen             | 42                  |
| Standardized regimen               | 14                  |
| Individualized and standardized    | 2                   |
| regimen*                           |                     |
| Not reported                        | 1                   |
| Frequency of and risk factors      | 17\(^b\)            |
| for adverse effects                |                     |
| Drug resistance amplification,     | 1                   |
| re-infection                       |                     |
| Delivery                           | 13\(^c\)            |
| Evaluation of treatment            |                     |
| completion and/or adherence\(^d\) |                     |
| Comparing interventions for        | 5\(^c\)             |
| enhancing completion/adherence     |                     |
| Frequency of and risk factors      | 3                   |
| for non-completion or non-adherence\(^a\) |             |
| Evaluation of role of nurses in    | 1                   |
| treatment support                  |                     |
| Description drug ordering system   | 1                   |
| Implementation and coverage of      | 1                   |
| second-line treatment              |                     |
| Analysis of treatment enrolment    | 1                   |
| Comparison of methods for          | 1                   |
| treatment monitoring               |                     |
| **Cost-effectiveness**             | 2\(^f\)             |
| **Study design**                   |                     |
| **Design**                         |                     |
| Comparative studies                | 7                   |
| Individually randomized trials     | 2                   |
| Group-randomized trials            | 0                   |
| Non-randomized cohort comparisons  | 3                   |
| Before-after comparisons            | 2                   |
| Non-comparative studies            | 65                  |
| Prospective cohort studies         | 22                  |
| Retrospective cohort studies       | 40                  |
| Case-control studies               | 1                   |
| Other                              | 2                   |
| **Setting**                        |                     |
| Estimated TB incidence per 100,000 | 72                  |
| population (2005) [62]             |                     |
| <50                                | 8                   |
| 50–99                              | 18                  |
| 100–299                            | 36                  |
| 300+                               | 8                   |
| Various                            | 2                   |
| Estimated MDR prevalence among     | 72                  |
| new TB patients (1994–2007) [63]   |                     |
| <3%                                | 41                  |
| 3–6%                               | 18                  |
| >6%                                | 11                  |
| various                            | 2                   |
| Appraisal                          | Total, n=72 | Minor Category |
|-----------------------------------|-------------|----------------|
|                                   | Major Category | Minor Category |
| Study location                    | 72          | 0              |
| Research setting                  |             | 0              |
| DOTS-Plus pilot project           |             | 21             |
| Routine—specialized clinic        |             | 27             |
| Routine – programmatic            |             | 21             |
| Various                           |             | 3              |

Generalizability

Study results are generalizable: 72
- Irrespective of epidemiological or health care setting: 53
- To similar epidemiological or health care settings: 19
- Not beyond national/local setting: 0
- Other: 0

Methods aimed at establishing (relevant studies): 62
- Efficacy: 4
- Effectiveness: 57
- Mixed: 1

*Studies covering multiple sites or periods.
*Including eight studies that evaluated treatment outcomes.
*Including two studies that did so by (also) evaluating treatment outcomes.
*Studies testing a hypothesis about measures to improve treatment completion or adherence.
*As specific study objective, no hypothesis testing about measures to improve treatment completion or adherence.
*Also addressing treatment outcomes.
*Number of studies evaluating effects on health.

doi:10.1371/journal.pmed.1001358.t003

Figure 6. Distribution of published studies on provision of second-line treatment for drug-resistant TB, by geography, objective, and study setting. Effectiveness studies relate to studies designed to address effectiveness as well as mixed effectiveness-efficacy for health-related outcomes, done in programmatic settings or “DOTS-Plus” pilots. Delivery relates to studies designed to address treatment completion and adherence, and organization of services. One non-comparative delivery study and two cost-effectiveness studies were also included as effectiveness studies.
doi:10.1371/journal.pmed.1001358.g006
throughout about how the development of the Xpert MTB/RIF, a fully automated cartridge-based nucleic acid amplification assay that was endorsed by the WHO in December 2010, may catalyse studies on operational aspects of this test, its effectiveness in program conditions, and its cost-effectiveness. Furthermore, this review underscores the need for novel and creative thinking to address the gaps that are occurring between global policy recommendations on new interventions and their real-life implementation in control programs, and that severely hamper efficient TB control. A broad concerted effort is urgently needed to develop operational-research capacity, allocate appropriate resources, and encourage all actors to work together [60] to promote the use of rational and objective-driven operational research in TB control to suitably inform policy making [59] as identified by the Global Plan to Stop TB 2011–2015, which incorporates research as a priority to improve TB control globally [2]. This effort may require funding agencies to reconsider their priorities. The 208 publications that we included in our review constitute only a minute fraction of the 81,854 publications on TB over the review period that were listed in PubMed alone, which included, for example, 591 papers on interferon-gamma release assays that are of very limited use in countries with high TB incidences [61]. Further, it requires not only that more operational studies are conducted, but also that the results are made publicly available, thus placing responsibilities with researchers, funding agencies, and journal editors.

Supporting Information

Text S1 PRISMA statement.

Text S2 Review protocol.

Text S3 Search strategies, details of included studies, and full reference list.

Author Contributions

Conceived and designed the experiments: FC RA CL. Performed the experiments: EO FC. Analyzed the data: SvK FC. Contributed reagents/materials/analysis tools: N/A. Wrote the first draft of the manuscript: FC. Contributed to the writing of the manuscript: FC SvK EO RA CL. Selected the papers: EO FC. Performed the appraisal: SvK FC.

References

1. (2010) Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization.
2. Stop TB Partnership, World Health Organization (2010) The Global Plan to Stop TB, 2011–2015. Geneva: World Health Organization.
3. Lienhardt C, Cobelens FGJ (2011) Operational research for improved tuberculosis control: the scope, the needs and the way forward. Int J Tuberc Lung Dis 15: 6–13.
4. Schünemann HJ, Schünemann AHJ, Osman AD, Brezuk J, Glassiou P, et al. (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336: 1106–1110.
5. Last JM (2000) A dictionary of epidemiology. 4th edition. New York: Oxford University Press.
6. Sanders D, Haines A (2006) Implementation research is needed to achieve international health goals. PLoS Med 3: e106. doi:10.1371/journal.pmed.0030106
7. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, et al. (2007) Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 297: 380–386.
8. Pai M, Minion J, Steingart K, Ramsay A (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16: 271–279.
9. Mann G, Squire SB, Rissell K, Elinee P, Du Toit E, et al. (2010) Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 14: 1518–1524.
10. Vaisala A, Compernelle P (2006) Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners. Health Policy 79: 1–15.
11. Tuberculosis (z.d.). Available: http://www.stoptb.org/global/plan/main/default.asp. Accessed 2 Nov 2010.
12. Onozaki I, Raviglione M (2010) Stopping tuberculosis in the 21st century: goals and strategies. Respirology 15: 32–43.
13. Stop TB Partnership: TB/HIV working group (2003) Guidelines for implementing collaborative TB and HIV programme activities. Geneva: World Health Organization.
14. World Health Organization (2006) Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization.
15. WHO (2003) Treatment of tuberculosis guidelines for national programmes. 3rd edition. Geneva: World Health Organization.
16. WHO (2007) Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization.
17. WHO (2000) Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization.
18. Duruvin B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, et al. (2010) The implementation of ironizad preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRi-o) study. AIDS 24 Suppl 5: S49–56.
19. Grant AD, Coetzee I, Fielding KL, Lewis J, Nthuie S, et al. (2010) “Team up against TB”: promoting involvement in Thulaba TB, a trial of community-wide tuberculosis preventive therapy. AIDS 24 Suppl 5: S57–44.
20. Mello FC de Q, Bastos LG do V, Soares SLH, Rezende VMC, Conde MB, et al. (2006) Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional study. BMC Public Health 6: 43.
21. Lambert ML, Sagulé H, Seyoum D, Abdurahman S, Abdimar A, et al. (2003) How can detection of infectious tuberculous be improved? Experience in the Somali region of Ethiopia. Int J Tuberc Lung Dis 7: 495–498.
22. World Health Organization (2007) Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization.
23. Holtz TH, Kabera G, Mhiyiane T, Zungsi T, Nadesan S, et al. (2011) Use of a WHO-recommended algorithm to reduce mortality in severely ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 11: 533–540.
24. Al-Hassan O, Salama L, Goume M, Vargas D, et al. (2010) Performance of a novel diagnostic test in smear-negative pulmonary tuberculosis in HIV prevalent settings. J Acquir Immune Defic Syndr 57: e53–e60.
25. Soto A, Solari L, Gotuzzo E, Arinelli R, Vargas D, et al. (2011) Performance of an algorithm based on WHO recommendations for the diagnosis of smear-negative pulmonary tuberculosis in patients without HIV infection. Trop Med Int Health 16: 484–490.
26. Koole O, Tai S, Khun KE, Pe R, van Grienven J, et al. (2011) Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS ONE 6: e18502. doi:10.1371/journal.pone.0018502
27. Wilson D, Mihale L, Badri M, Morenzi C, Nachega J, et al. (2011) Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated smear-negative tuberculosis. Int J Tuberc Lung Dis 15: 919–924.
28. Yang HZ, Grange G, Liang LT, Dung NH, Lan NTV, et al. (2011) Improving the diagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho chi Minh City, Vietnam. Int J Tuberc Lung Dis 15: 1328–1334.
29. Van Deun A, Maqg AKJ, Salim MAH, Das PK, Sarker MR, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 694–692.
30. Lovdevy M, Wallengren K, Voce A, Margot R, Reddy T, et al. (2012) Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 16: 209–215.
31. Leitmaar V, Dravnieck G, Riekkinta V, Sture I, Kammmerer S, et al. (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur. Respir J 36: 584–593.
32. Podelwiz JH, Holtz T, Riekkinta V, Skirosca V, Zarovka E, et al. (2011) Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiol Infect 139: 113–120.
33. Clark PM, Karagdag T, Apikoglu-Rabus S, Izzettin FV (2007) Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm 64: 497–503
34. Kunawaharak P, Pongsanich S, Chantasong S, Pokaw P, Traisith P, et al. (2011) Tuberculosis treatment with mobile-phone medication reminders in northern Thailand. Southeast Asian J Trop Med Public Health 42: 1444–1451.
35. Quelapio MID, Mira NRC, Orilaza-Chi RB, Belen V, Matiez N, et al. (2010) Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Int J Tuberc Lung Dis 14: 731–737.
36. Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, et al. (2010) Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 14: 420–426.
37. Acha J, Sweetland A, Guerra D, Chalo K, Castillo H, et al. (2007) Psychosocial support groups for patients with multidrug-resistant tuberculosis: five years of experience. Glob Public Health 2: 404–417.
38. Bonnet M, Pardini M, Meacci F, Orrù G, Yesilkaya H, et al. (2011) Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE 6: e23081. doi:10.1371/journal.pone.00023081
39. Smith PG, Morrow RH (1991) Methods for field trials of interventions against tropical diseases: a toolbox. New York: Oxford University Press.
40. Murray DM (1998) Design and analysis of group-randomized trials. 1st edition. New York: Oxford University Press.
41. The Gambia Hepatitis Study Group (1987) The Gambia Hepatitis Intervention Study. Cancer Res 47: 5702–5707.
42. Huser MA, Hughes JP (2007) Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 28: 182–191.
43. Brown CA, Lilford RJ (2006) The stepped wedge trial design: a systematic review. BMC Med Res Methodol 6: 54.
44. Squire SB, Ramsay ARC, van den Hof S, Millington KA, Langley I, et al. (2011) Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 15: 862–870.
45. Nathanson E, Gupta R, Huamani P, Leimane V, Paschynikov AD, et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8: 1382–1384.
46. Nathanson E, Lambregts-van Wezenbeek C, Rich ML, Gupta R, Bayona J, et al. (2006) Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infect Dis 12: 1389–1397.
47. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, et al. (2008) Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3: e3001. doi:10.1371/journal.pone.0003001
48. Getahun H, Grandi R, Sculler D, Gunneberg C, Blanc L, et al. (2010) Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 24 Suppl 5: S37–63.
49. Getahun H, Harrington M, O’Brien R, Nunn P (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.
50. Getahun H, Harrington M, O’Brien R, Nunn P (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.
51. Cobelens FGF, Heldal E, Kimerling ME, Minnick CD, Pedevilla LJ, et al. (2008) Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 5: e130. doi:10.1371/journal.pmed.0050130
52. Mount FW, Feebee SH (1961) Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med 265: 715–721.
53. Feebee SH, Mount FW (1962) Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 83: 490–510.
54. Egnor T, Ang’awa JO, Poti SJ (1963) The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ 33: 419–433.
55. Del Castillo H, Bautista L, Jacinto C, Lorenzo C, Lapaz S, et al. (1965) Chemoprophylaxis in the Philippines. A controlled pilot study among household contacts of tuberculosis cases. Bull Quezon Institute 7: 277–290.
56. Comstock GW, Feebee SH, Hammes LM (1967) A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 95: 935–943.
57. Kochi A (1997) Tuberculosis control— is DOTS the health breakthrough of the 1990s? World Health Forum 18: 225–232.
58. Stop TB Partnership (2011) An international roadmap for tuberculosis research. Geneva: World Health Organization. Available: www.stoptb.org/assets/
59. Stop TB Partnership, The Global Fund to Fight AIDS, Tuberculosis and Malaria (2011) Priorities in operational research to improve tuberculosis care and control. Geneva: World Health Organization.
60. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, et al. (2010) Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 375: 2178–2191.
61. World Health Organization (2011) Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement.WHO/HTM/TB/2011.18. Available: http://www.who.int/tb/publications/2011/en/index.html. Geneva: World Health Organization.
62. WHO (2006) WHO Report 2006: Tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization.
63. WHO (2008) Anti-tuberculosis drug resistance in the world. Fourth global report. Geneva: World Health Organization.
64. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, et al. (2009) A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 62: 464–473.
65. Cahn KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, et al. (2010) An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 362: 707–716.
66. Monkongdee P, McCarthy KD, Cahn KP, Tasaneeyapan T, Nguyen HD, et al. (2009) Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 180: 903–908.
Editors’ Summary

Background. Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, is curable and preventable, but according to the World Health Organization (WHO), in 2011, 8.7 million people had symptoms of TB (usually a productive cough and fever) and 1.4 million people—95% from low- and middle-income countries—died from TB. TB is also the leading cause of death in people with HIV worldwide, and in 2010 about 10 million children were orphaned as a result of their parents dying from TB. To help reduce the considerable global burden of TB, a global initiative called the Stop TB Partnership, led by WHO, has implemented a strategy to reduce deaths from TB by 50% by 2015—even greater than the target of Millennium Development Goal 6 (to reverse the increase in TB incidence by 2015).

Why Was This Study Done? Over the past few years, WHO has recommended that countries implement several interventions to help control the spread of tuberculosis through measures to improve prevention, diagnosis, and treatment. Five such interventions currently recommended by WHO are: treatment with isoniazid to prevent TB among people who are HIV positive, and also among household contacts of people infected with TB; the use of clinical pathways (algorithms) for diagnosing TB in people accessing health care who have a negative smear test—the most commonly used diagnostic test, which relies on sputum samples (“rule-in algorithms”); screening algorithms for excluding TB in people who have HIV (“rule-out algorithms”); and finally, provision of second-line treatment for multidrug-resistant tuberculosis (a form of TB that does not respond to the most commonly used drugs) under programmatic conditions. The effectiveness of these interventions, their costs, and the practicalities of implementation are all important information for countries seeking to control TB following the WHO guidelines, but little is known about the availability of this information. Therefore, in this study the researchers systematically reviewed published studies to find evidence of the effectiveness of each of these interventions when implemented in routine practice, and also for additional information on the setting and conditions of implemented interventions, which might be useful to other countries.

What Did the Researchers Do and Find? Using a specific search strategy, the researchers comprehensively searched through several key databases of publications, including regional databases, to identify 208 (out of 11,489 found initially) suitable research papers published between January 1990 and March 2012. For included studies, the researchers also noted the geographical location and setting and the type and design of study. Of the 208 included studies, 59 focused on isoniazid prevention therapy in HIV infection, and only 14 on isoniazid prevention therapy for household contacts. There were 44 studies on “rule-in” clinical diagnosis, 19 on “rule-out” clinical diagnosis, and 72 studies on second-line treatment for TB. Studies on each intervention had some weaknesses, and overall, researchers found that there were very few real-world studies reporting on the effectiveness of interventions in program settings (rather than under optimal conditions in research settings). Few studies evaluated the methods used to implement the intervention or addressed delivery and operational issues (such as adherence to treatment), and there were limited economic evaluations of the recommended interventions. Furthermore, the researchers found that in general, the South Asian region was poorly represented.

What Do These Findings Mean? These findings suggest that there is limited evidence on effectiveness, delivery, and cost-effectiveness to guide the scale-up of five WHO recommended interventions to control tuberculosis in the countries and settings, despite the urgent need for such interventions to be implemented. The poor evidence base identified in this review highlights the tension between the decision to adopt the recommendation and its implementation adapted to local circumstances, and may be an important reason as to why these interventions are not implemented in many countries. This study also suggests creative thinking is necessary to address the gaps between WHO recommendations and global health policy on new interventions and their real-world implementation in country-wide TB control programs. Future research should focus more on operational studies, the results of which should be made publicly available, and researchers, donors, and medical journals could perhaps re-consider their priorities to help bridge the knowledge gap identified in this study.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001358.

- WHO has a wide range of information about TB and research on TB, including more about the STOP TB strategy and the STOP TB Partnership
- The UN website has more information about MDG 6
- The Global Fund to Fight AIDS, Tuberculosis and Malaria has specific information about progress on TB control